Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against Covid-19 the I.D.E.A. Protocol

Carvallo Hector\(^1\), Hirsch Roberto\(^2\)

\(^1\)Department of Internal Medicine, Universidad Abierta Internamericana, San Juan, Argentina; \(^2\)Department of Infectology, Universidad de Buenos Aires, Caba, Argentina

ABSTRACT

From the first outbreak in Wuhan (China) in December 2019, until today (05/28/2020), the number of deaths worldwide due to the coronavirus pandemic exceeded 2.5 millions. Only in Argentina, 50,000 deaths have been confirmed so far. There haven’t been so far any clear diagnostic pattern for this exceptional entity except unilateral skin involvement, early onset of symptoms, positive ANA and negative tests for Borrelia burgdorferi. Hence, we report a new case of a young Moroccan man.

No treatment tested worldwide has shown unquestionable efficacy in the fight against COVID 19, according to W.H.O, NIH and NICE reports and accumulated data.

Our proposal consists of the combination of drugs, based on the pathophysiology of the virus. We have designed a treatment called I.D.E.A., based on four affordable drugs already available on the pharmacopoeia in Argentina, on the following rationale:

- Ivermectin (IVM) solution to lower the viral load in all stages of COVID 19
- Dexamethasone 4-mg injection, as anti-inflammatory drug to treat hyperinflammatory reaction to COVID-infection
- Enoxaparin injection as anticoagulant to treat hypercoagulation in severe cases.
- Aspirin 250-mg tablets to prevent hypercoagulation in mild and moderate cases

Except for Ivermectin oral solution, which was used in a higher dose than approved for parasitosis, all other drugs were used in the already approved dose and indication. Regarding Ivermectin safety, several oral studies have shown it to be safe even when used at daily doses much higher than those approved already. A clinical study has been conducted on COVID-19 patients at Eurnekian Hospital in the Province of Buenos Aires, Argentina.

The study protocol and its final outcomes are described in this article. Results were compared with published data and data from patients admitted to the hospital receiving other treatments.

None of the patient presenting mild symptoms needed to be hospitalized. Only one patient died (0.59 % of all included patients vs. 2.1 % overall mortality for the disease in Argentina today; 3.1 % of hospitalized patients vs. 26.8 % mortality in published data). I.D.E.A. protocol has proved to be a very effective alternative to prevent disease progression of COVID-19 when applied to mild cases, and to decrease mortality in patients at all stages of the disease with a favorable risk-benefit ratio.

Keywords: Ivermectin; Aspirin; Dexamethasone; Enoxaparin; Covid-19; I.D.E.A.
INTRODUCTION

In late December 2019, the incidence of atypical pneumonia cases of unknown cause was reported in the Chinese city of Wuhan.

PCR (Polymerase Chain Reaction) studies found a coronavirus, which was >85% similar to a bat SARS-type CoV (bat-SL-CoVZC45).

SARS-type CoV (bat-SL-CoVZC45)

The early association identified between SARS-CoV with SARS-CoV-2 was supported by subsequent analyses, where an important similarity in these transmembrane structures was made clear.

The only significantly different portion is a furin-binding domain in the SARS-CoV-2 protein S, which may expand tropism or increase virus transmission.

Studies on SARS-CoV proteins have revealed a potential role for IMPα1 during infection in the signal-dependent nucleocapsid closure of the SARS-CoV nucleocapsid protein, which may affect host cell division. The predilection and competitiveness of the virus over ACE2 cell receptors has already been demonstrated, and its subsequent need for the importin described above is also confirmed. This functional receptor is found in multiple tissues, including alveolar epithelium of the lung, arterial and venous endothelium, smooth muscle, renal tubular epithelium, oropharyngeal mucosa and epithelium of the small intestine, largely explaining the clinical presentation of patients with COVID-19. So has its interaction with TMPRSS2 receptors (Figure1).

![Figure 1: COVID 19 and ACE2 receptors](image)

DEVELOPMENT OF CLINICAL EVENTS

Before proceeding to list them, we must emphasize two premises:

Between 30 and 50% of patients who contract COVID 19 will be asymptomatic or oligosymptomatic. This fact will not give rise to the consultation, and will directly affect a notorious under-registration of the cases.

The second, even more disturbing, premise is that these patients are as contagious as the moderate and severe cases.

The virus incubation period has been calculated at 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of patients are said to have symptoms at 11 days (95% CI 8.2 to 15.6 days).

A mortality of 3.1% has been calculated. The average COVID patient presents with fever (78%), cough (60-79%) and myalgias or fatigue (35.8 to 44%).

55% develop dyspnea, which appears on average 8 days after the onset of symptoms.

To the manifestations expressed above, the presence of bilateral conjunctival injection should be added, without associated secretions, hypogeusia, skin rash and hyposmia.

Diagnostic confirmation is made through laboratory studies, which can be performed on a wide variety of biological samples.

Bronchoalveolar lavage samples showed the highest sensitivity (93%), followed by sputum samples (72%), nasal swabs (63%), fiberoptic brush biopsy (46%), pharyngeal swabs (32%), feces (29%) and, finally, blood (1%). A sensitivity of 91% is reported in saliva samples.

Computed Axial Tomography (CAT) is very useful as a complementary study in the diagnostic approach of COVID-19, but this does not discredit follow-up by conventional Radiology, if more sophisticated means are not available.

Evidence suggests that a subgroup of patients with severe forms of COVID 19 may have cytokine storm syndrome.

Therefore, we recommend the identification and treatment of hyperinflammation using existing approved therapies with proven safety profiles to address the immediate need to reduce increasing mortality (see Therapeutic Proposal).

Secondary Hemophagocytic Lymphohistiocytosis (SHLH) is a poorly recognized hyperinflammatory syndrome characterized by fatal and fulminant hypercytokinemia with multiple organ failure.

In adults, SHLH is most often triggered by viral infections, and occurs in 3.7-4.3% of sepsis cases.

The cardinal features of SHLH include constant fever, cytopenias, and hyperferritinemia; Pulmonary involvement (including ARDS) occurs in approximately 50% of patients.

A cytokine profile that resembles SHLH is associated with the severity of COVID-19 disease, characterized by an increase in interleukin (IL) -2, IL-7, granulocyte colony stimulating factor, protein 10 inducible by interferonγ, monocyte chemoattractant protein, macrophage inflammatory protein 1α and tumor necrosis factor-α.

Mortality predictors from a recent multicenter retrospective study of 150 confirmed cases of COVID-19 in Wuhan, China included elevated ferritin (mean 1297.6 ng / ml in non-survivors versus 614.0 ng / ml in survivors; p<0.001) and IL-6 (p<0.0001), suggesting that mortality could be due to viral hyperinflammation (Figure 2).
Figure 2: Aggressive forms of infection.

However, cases have been reported where tissue and organ involvement has been found whose concentration of ACE receptors is very dissimilar (myocardium, brain). In all of them, the common denominator was small vessel thrombosis, as seen in entities such as Catastrophic Antiphospholidic Syndrome.

More than a century ago, Virchow proposed that the formation and spread of thrombi was caused by abnormalities in three key areas:

- **Blood flow**
- **The vascular wall**
- **The components of blood**

These three factors are known as the Virchow triad (Figure 3).

Currently the Virchow triad factors have been narrowed down in more detail:

- Circulatory stasis: abnormalities of hemorrheology and turbulence in vascular bifurcations and stenotic regions.
- Injury to the vascular wall: abnormalities in the endothelium, such as atherosclerosis and associated vascular inflammation.
- Hypercoagulable state: abnormalities in the coagulation and fibrinolytic pathways and in platelet function associated with an increased risk of VTE and other cardiovascular diseases (such as Coronary Artery Disease [CPA], heart failure and stroke in patients with AF). All lead to a state of hypercoagulability, which could explain the formation of microthrombosis in different locations, as has been repeatedly reported in patients with COVID 19.

**BASES OF THE PROPOSED THERAPEUTICS**

They rest on four pillars: Ivermectin, Aspirin, Dexamethasone and Enoxaparin.

**IVERMECTIN**

Ivermectin is a broad-spectrum antiparasitic, with vermicidal and ectoparasiticidal properties. It was discovered and marketed for animal use in the early 1980s.

Approved in 1997 by the FDA for single-dose strongyloidiasis of 200 mcg /kg and crusted scabies (Scabies Norway) in patients with AIDS at a dose of 200 mcg/kg, every week for 2 weeks.

In Argentina, it has been available for human use for almost 20 years.

But, much more recently, its viricidal effects have been compiled on different varieties of flavivirus, dengue, Zika, Chikungunya, etc.

Ivermectin has been reported to be a SARS-CoV-2 inhibitor. This activity is believed to be due to the dependence of many different RNA viruses on IMPα/β during infection. These reports suggested that the inhibitory activity of ivermectin nuclear transport may be effective against SARS-CoV-2, since they demonstrate that ivermectin has antiviral action against the clinical isolate of SARS-CoV-2 in vitro, with a single dose capable to control viral replication in 24-48 hours in vitro.

Apart from the intracellular effect of IVM, more mechanisms of action have been described (Figure 4).

**ASPIRIN**

Aspirin is the common name for acetylsalicylic acid. The chemical production is based on the salicylic acid obtained by synthesis. Its most common uses and for what it was first used was as an analgesic (for pain), antipyretic (to lower fever) and anti-inflammatory. It is classified as a non-steroidal anti-inflammatory drug (NSAID). In 1989 the first large study was published that proved that Aspirin reduces cardiovascular risk, acting as an antplatelet agent.

These were low-dose Aspirin, and the risk of myocardial infarction was found to decrease by 44% when the previously named dose of Aspirin was administered.

**HEPARIN AND ENOXAPARIN**

Heparins are injectable anticoagulant substances. A distinction should be made between standard heparin or unfractionated heparin (HNF) and low molecular weight heparins (LMWH).

HNF is made up of a heterogeneous mixture of polysaccharide...
chains of variable length.

LMWHs are the result of fragmentation of HNF by different methods to achieve products with lower and more homogeneous molecular weights. They are also made up of a mixture of polysaccharide chains and their average molecular weight is much lower. The antithrombotic and anticoagulant activity of HNF is related to the ability to inhibit factor Xa and factor IIa respectively. LMWHs have less inhibitory activity to thrombin or factor IIa but maintain the same potency with respect to factor Xa, so it is expected that they present a lower risk of bleeding but the same antithrombotic activity.

CORTICOSTEROIDS

Systemic corticosteroids are powerful anti-inflammatory and immunosuppressive agents. They can be administered intravenously, intramuscularly, orally, intranasally, and topically. Its side effects increase with high, long and frequent doses.

Corticosteroids are drugs frequently used in various clinical situations, because they are powerful anti-inflammatories and immunomodulators.

Glucocorticoids passively diffuse through the cell membrane, then join soluble receptor proteins in the cytoplasm. They are used, among others, for the treatment of some rheumatic diseases. A separate case, well known but not studied in the current contingency, is acute adrenal insufficiency. The RECOVERY Trial proved DM is useful to reduce mortality.

Table 1: Criteria.

<table>
<thead>
<tr>
<th>MINOR CRITERIA</th>
<th>MAJOR CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever less than 38.5 °</td>
<td>Fever higher than 38.5 °</td>
</tr>
<tr>
<td>Isolated diarrheal episodes</td>
<td>Diarrhea (more than 3 diarrheic stools / day)</td>
</tr>
<tr>
<td>Hyposmia or Hypogeusia</td>
<td>Flictenular conjunctivitis</td>
</tr>
<tr>
<td>Mild desaturation (between 96 and 93%)</td>
<td>Strong desaturation (less than 92%)</td>
</tr>
<tr>
<td>Dyspnea without matter</td>
<td>Tachypnea (FR&gt; 25 / minute)</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td>Livedo reticularis</td>
</tr>
<tr>
<td>Persistent headache</td>
<td>Giant urticaria</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Interpretation.

<table>
<thead>
<tr>
<th>Mild cases</th>
<th>Moderate cases</th>
<th>Severe cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only minor crit.</td>
<td>3 major crit.</td>
<td>4 major crit.</td>
</tr>
<tr>
<td>criteria findings</td>
<td>findings,</td>
<td>Findings or 3</td>
</tr>
<tr>
<td></td>
<td>or 2 major + 2 minor</td>
<td>major + 2 minor</td>
</tr>
</tbody>
</table>

Table 3: Disease severity.

<table>
<thead>
<tr>
<th>Disease severity</th>
<th>Ivermectin</th>
<th>Corticoid</th>
<th>Ventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Firm Suspicious Case or Confirmed case</td>
<td>24 mg orally at a dose of 200 ug / kg in a single dose, to be repeated a week later</td>
<td>No</td>
<td>Aspirin 250 mg orally</td>
</tr>
<tr>
<td>Moderate clinical stage</td>
<td>36 mg orally at a dose of 400 ug / kg in a single dose, to be repeated a week later</td>
<td>Dexamethasone 4 mg (parenteral)</td>
<td>idem</td>
</tr>
<tr>
<td>Severe case with bilateral pneumonia</td>
<td>48 mg via gastric cannulae, at a dose of 600 ug/kg in a single dose, to be repeated a week later</td>
<td>idem</td>
<td>Enoxaparin 100 UI/kg (1 mg/kg)</td>
</tr>
</tbody>
</table>

Table 4: Equivalences.

Dose of 300 micrograms/kg orally, 0.6% drops=1.5 drops/kg of weight
Dose of 400 micrograms/kg orally, 0.6% drops=2.25 drops/kg of weight
Dose of 600 micrograms/kg orally, 0.6% drops=3 drops/kg of weight

When possible, we preferred to use IVM solution instead of tablets, because of its easier absorption and the velocity to reach Tmax and tissue concentration. Solution is also a better alternative if gastric cannulae shall be used.

OUTCOMES

According to our clinical criteria, patients were divided into two major groups: outpatients and admitted patients. Among the admitted patients (Figure 5), death rate was 7 times less with the I.D.E.A. protocol, if compared to all other applied treatments. In this case, it is important to mention that corticosteroids and or enoxaparin were used on both arms.

It is important to emphasize that death was taken as final “adverse reaction”, thus avoiding any subjective bias.

Figure 5: Outcomes in admitted patients.
In the outpatients’ group, the adverse effect considered was the need of ulterior admittance, as it has been observed worldwide that this happens in up to 10 % of the mild cases, during the two weeks posterior to diagnosis.

None of those 135 patients (0,0 %) needed to be admitted (Fig. 6)

<table>
<thead>
<tr>
<th>Total:</th>
<th>135 patients with + swabs but without admittance criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average Age:</td>
<td>53.5 years</td>
</tr>
<tr>
<td>Sex Predominance:</td>
<td>not significant</td>
</tr>
<tr>
<td>Medication:</td>
<td>Ivermectin 24 mg. oral, to be repeated a week later</td>
</tr>
<tr>
<td>AAS 250 mg. oral, on a daily basis</td>
<td></td>
</tr>
<tr>
<td>Need of ulterior admittance: zero</td>
<td></td>
</tr>
</tbody>
</table>

Figure 6: Mild cases outcomes.

CONCLUSION

Given the rapid advance of the pandemic, the sequel of death that it leaves behind, the lack of sustainable evidence in the experimental treatments proposed up till now, the presence of all the drugs proposed by us in the national pharmacopoeia, their low cost in relation to the other trials, the scarce incidence of side effects, and the possibility of massive use without the limitations of dose, we conclude that the combination ivermectin + aspirin + dexamethasone + enoxaparin is a very desirable alternative.

Since we finished our Trials, 54 more ones have been submitted to the NLM (USA), 35 of which already contain results. A meta-analysis of those 37 Trials concluded all of them had positive results, and the possibility of bias was almost inexistent (Figure 7).

Figure 7: Meta-Analysis of trials using Ivm.

ACKNOWLEDGEMENT

This Trial received no public or private funding.

Conflict of Interest

The Authors manifest no conflict of interests.

REFERENCES


10. NICE COVID-19 rapid evidence summary: angiotensins-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19


16. ClinicalTrials.gov Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) (CORON-ACT) Sponso... Information provided by (Responsible Party): University Hospital Inselspital, Berne


24. Chilinh Nguyen et al.: Evaluation of a novel West Nile virus transmission control strategy that targets Culex tarsalis with endectocide-containing blood meals. 2019
25. Ivermectina: sus múltiples usos, seguridad y toxicidad JV Ch - 2010 - sochiderm.org
28. Leon Caly; Julian D.Druce; Mike G.Carton; David A.Jans; Kylie M.Wagstaff The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020
32. Patel, Amit et al: Usefulness of Ivermectin in COVID-19 Illness. Department of Bioengineering, University of Utah, Salt Lake City, MMEHRA@BWH.HARVARD.EDU
35. Kelvin Kai-Wang To: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2; an observational cohort study., www.thelancet.com/infection Published online March 23, 2020
38. G. Edwards, A. Dingsdale, N. Helsby, M. L’E. Orme, and A. M. Breckenridge: The Relative Systemic Availability of Ivermectin After Administration as Capsule, Tablet, and